Abstracts 473 transitions from one state to another within discrete time frames (6 months). The states were: non-user; has sampled (has tried); non-dependent user; ex-user; dependentnot treated; dependent-treated; abstinent; death. The average quantity of heroin demanded was determined at the cohort level, based on published price and income elasticities. Scenario-analyses showed the impact of variations in different parameters and the effects of different policy measures on the results. Using a bottom-up approach, the results were then aggregated to a population level. RESULTS: Calculating the 20-year demand for heroin on a cohort level generated an average demand between 5.96g to 20.45g per European citizen, depending on different variables in the model. Sub-analyses showed that a 50% increase in the price level of heroin could have a negative impact of 72% on total heroin demand. A decrease in sampling of 50% generated an almost equal impact on total heroin demand. Analyzing the impact of substitution treatment indicated that easier access to treatment and a longer follow-up after completing treatment would have a greater impact than the success of treatment itself in achieving abstinence. CONCLUSIONS: This is the first macro-economic model designed for policy makers to assess the impact of measures to control problematic drug use. Measures aimed at preventing a first heroin dose and controlling the price of heroin seem to be worth focussing on.
what is it trying to measure?). Two tests of external validity were used to relate the performance of each indicator to other measures of the same construct (concurrent validity and predictive validity). In addition we used a published method to test the robustness of ranking of General Practices by each prescribing indicator. We obtained data for all 78 General Practices in Tayside for the years 1993-97. RESULTS: We identified five prescribing indicators that had been previously tested for face validity in a two-stage Delphi consultation study. These were: 1) the ratio of bendrofluazide 2.5mg to total bendrofluazide items; 2) the ratio of generic items to all items; 3) the ratio of trimethoprim to trimethoprim/sulphamethoxazole; 4) the ratio of antibiotics from the primary-care formulary to all antibiotics; and, 5) the ratio of maintenance dose of proton pump inhibitors to all PPI items. Crude ranking of general practices compared well with the results of the more robust rankings generated by the Marshall and Spiegelhalter ranking. There were significant improvements in the achievement of all five indicators by Tayside practices from 1993 to 1997, and ranking of each practice was robust over time. However, there was no relationship between an individual practice's ranking by different indicators. CONCLUSIONS: Differences between practices are statistically robust and practices have shown significant improvements in all indicators over time. However, the absence of concurrent validity between indicators casts doubt on their use as measures of general prescribing quality.
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USING PRESCRIBING DATA TO ESTIMATE PREVALENCE OF CHRONIC ILLNESS IN THE REPUBLIC OF IRELAND McElroy B University College Cork, Cork, Ireland
OBJECTIVES:
We use the Chronic Disease Score methodology to estimate the prevalence of a number of chronic conditions in the Republic of Ireland from routinely available prescribing data, which we then compare with epidemiological estimates. METHODS: Using automated outpatient pharmacy data, measures of chronic disease severity called Chronic Disease Scores were constructed. We use these to measure disease prevalence. Since many drugs have multiple indications, incidental users and the chronically ill must be distinguished. Any person receiving four or more prescriptions within a 12-month period for a chronic disease category is identified as suffering from that chronic disease. Prevalence estimates are compared with estimates for these conditions based on a review of the epidemiology literature. Data refer to the General Medical Services (GMS) scheme in Ireland. The GMS provides free primary care to those on low income and to other hardship cases, covering approximately 31% of the Irish population. Data on drugs prescribed to all individuals on the GMS scheme in four health board areas were collected for the period from September 1999 to August 2000, representing a total of 415,271 people or approximately 37% of the GMS population. RESULTS: Estimates of prevalence based on the Chronic Disease Score are similar to epidemiological estimates. This is especially true for conditions such as diabetes, epilepsy and asthma, and less so for depression and other mental illness, where under-diagnosis is commonplace. CONCLUSIONS: The results suggest that prescribing data is a rich source of information on morbidity in the community. It is locally sensitive, timely and cheap to collect. As long as certain caveats are applied, this type of information has many uses in the surveillance of the public's health.
